Intervention effects of different brands of botulinum toxin type A on Meige syndrome with anxiety symptoms

Patients with Meige syndrome are often affected by anxiety symptoms, and drug therapy is the primary treatment option, with botulinum toxin A being the most frequently used medication. This study analyzes the intervention effects of different brands of botulinum toxin A on Meige syndrome with anxiety symptoms. The findings aim to provide a theoretical basis for the rational selection of clinical treatment options.

A retrospective analysis was conducted on 148 patients treated between January 2021 and December 2023. Patients were divided into two groups based on the BoNT-A brand received: Chinese botulinum toxin type A (Hengli) group (n = 80) and onabotulinumtoxinA (Botox) group (n = 68). Both groups received local injections at the sites of muscle spasms. The outcomes included the degree of spasm relief, duration of efficacy, scores on the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS), polysomnography parameters [sleep efficiency (SE), total sleep time (TST), sleep latency (SL), number of wakefulness (AI), rapid eye movement sleep time (REMS)], and adverse reactions.

There were no statistically significant differences in the total remission rate and efficacy maintenance time between the two groups (p > 0.05). The differences in the scores of the SAS, SDS, SE, TST, SL, AI, and REMS before and after treatment between the two groups were not statistically significant (p > 0.05). There was no statistically significant difference between the two groups when comparing the incidence of adverse reactions such as incomplete eyelid closure, facial muscle weakness, and drooping of the corners of the mouth during expression muscle activity (p > 0.05).

Local injection of botulinum toxin type A is a safe and effective treatment for Meige syndrome with anxiety symptoms, and there is no significant difference in the efficacy, duration of action, and improvements in psychological state and sleep quality between different brands of botulinum toxin type A. Therefore, clinical practice should be based on practical considerations to reasonably select the appropriate brand of botulinum toxin type A for treatment.